Abstract
ABSTRACTThe role of ziconotide in managing severe, neuropathic cancer pain is described. This is illustrated by a case of a 63-year-old woman with breast cancer who had failed more conservative therapy but who responded to intrathecal ziconotide. Clinical efficacy and adverse effects of the drug are discussed. Commentaries on this case from the United Kingdom are provided by pain specialists from Spain and The Netherlands.The content of this case report appeared in: Wells CD (editor). Proceedings of the 3rd International Congress on Neuropathic Pain. NeuPSIG. Athens (Greece), May 27–30, 2010. Pianoro, Italy, Medimond Srl, 2010. ©MedimondSrl. Reproduced with permission. This feature is adapted from paineurope 2012; Issue 1, ©Haymarket Medical Publications Ltd., and is presented with permission. paineurope is provided as a service to pain management by Mundipharma International, Ltd., and is distributed free of charge to health care professionals in Europe. Archival issues can be accessed via the Web site: http://www.paineurope.com at which European health professionals can register online to receive copies of the quarterly publication.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
